Pharmaceuticals
IASO Bio Partners with Korea's GC Cell to Bring CAR-T Therapy to Korea
* Potential new treatment option for multiple myeloma patients in Korea. * Expanded patient access through competitive pricing. SHANGHAI and NANJING, China and PLEASANTON, Calif., Oct. 29, 2025 /PRNewswire/ -- Nanjing IASO Biotechnology ("IASO Bio"), today announced that it has signed an agree...
What Hebei Can Offer丨Biomedicine and Beyond
SHIJIAZHUANG, China, Oct. 29, 2025 /PRNewswire/ -- A News Report from Great Wall New Media -- Among Hebei Province's 107 key specialized industrial clusters, the biopharmaceutical cluster in Shijiazhuang High-Tech Zone has emerged as a model of high-quality development and a key engine drivingHeb...
A Breakthrough in Color Measurement Is Coming: The HunterLab Agera L2
RESTON, Va., Oct. 29, 2025 /PRNewswire/ -- A breakthrough in color measurement
is on the horizon. This November,HunterLab
Charming Medical Limited Announces Full Exercise of Representative's Over-allotment Option
HONG KONG, Oct. 28, 2025 /PRNewswire/ -- Charming Medical Limited (Nasdaq: MCTA) (the "Company"), a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products, today announced, in connection with its previously announced initial public offering (the "Offering")...
Harbour BioMed Launches First Fully Human Generative AI HCAb Model to Accelerate Next-Generation Biologics Discovery
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 28, 2025
/PRNewswire/ -- Harbour BioMed
SI GROUP OPENS NEW INNOVATION CENTER
State-of-the-art facility expands company's global research and development
capabilities
THE WOODLANDS, Texas, Oct. 28, 2025 /PRNewswire/ -- SI Group
Fosun Pharma Announces 2025Q3 Financial Results
Innovative Achievements Continue to Come to Fruition, Revenue from Innovative Drugs ExceedingRMB6,700 Million in The First Three Quarters of 2025 SHANGHAI, Oct. 28, 2025 /PRNewswire/ -- On October 28, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; SSE: 60019...
Xinhua Silk Road: Innovation, tradition deeply integrated on TCM trade fair in China's Zhangshu City
BEIJING, Oct. 28, 2025 /PRNewswire/ -- China's Zhangshu City, a famed
industrial hub of traditional Chinese medicine (TCM) for centuries, has
actively promoted integration of tradition and innovation forChina's
traditional medicines and medical treatment on its annual TCM fair.
Samsung Biologics reports third quarter 2025 financial results
* Recorded Q3'25 consolidated revenue of KRW 1,660.2 billion * Recorded Q3'25 consolidated operating profit of KRW 728.8 billion * Delivered consistent performance through stable capacity ramp-up and strengthened global partnerships INCHEON, South Korea, Oct. 28, 2025 /PRNewswire/ -- Samsung...
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Fast Track Designation by FDA for the Treatment of PROC
SUZHOU, China, Oct. 28, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of advanced or...
Fibronostics Acquires Stone Clinical Laboratories to Advance MASH/MASLD Diagnostics
Acquisition expands U.S. lab operations and accelerates innovation in non-invasive diagnostics for metabolic and liver diseases. NEW ORLEANS, Oct. 27, 2025 /PRNewswire/ -- Fibronostics, a global leader in non-invasive diagnostics for metabolic and liver diseases, today announced the completion o...
Shanton Pharma Completes EOP2 Meeting with US FDA for Refractory Gout Program
SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., Oct. 27, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech developing a novel treatment for gout, today announced the successful completion o...
BioDlink Completes First International Shipment of Bevacizumab to Colombia
* Bevacizumab is a targeted therapy used to treat lung and colorectal cancers, both among the top three cancers ranked by death inColombia[1]. * This inaugural shipment—dispatched around two months after Colombia's marketing approval—demonstrates the company's efficiency, while validating its ...
Daewoong Pharmaceutical: Third IDMC Reaffirms Safety of Bersiporocin and Recommends Continuation of Global Phase 2 Clinical Trial
* Third Independent Data Monitoring Committee (IDMC) review confirms safety and continuation of the study * 94 patients enrolled out of 102 planned across Korea and the U.S. * Interim baseline characteristics to be presented at the 2025 KATRD International Conference SEOUL, South Korea, Oct...
Raffles Medical Group Partners Gene Solutions to Expand Access to Global Cancer Clinical Trials
SINGAPORE, Oct. 27, 2025 /PRNewswire/ -- Raffles Medical Group
CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
Setting new standards in responsible innovation, CSL's Broadmeadows facility
blends Pharma 4.0™ principles with sustainable design to transform plasma
manufacturing
BROADMEADOWS, AUSTRALIA, Oct. 27, 2025 /PRNewswire/ -- CSL
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for Colorectal Cancer
SUZHOU, China, Oct. 27, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC P...
Antengene Presents Latest Preclinical Data of ATG-201 (CD19 x CD3 TCE) at ACR 2025
SHANGHAI and HONG KONG, Oct. 27, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for autoimmune dis...
Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3
* The proportion of participants achieving HbA1c < 7.0% and a ≥10% reduction in body weight from baseline was 48.0% in the mazdutide group and 21.0% in the semaglutide group * DREAMS-3 is the world's first Phase 3 clinical trial of a GCG/GLP-1 dual receptor agonist to conduct a head-to-head c...
Indonesia's Legacy in the Global Vaccine Landscape, Bio Farma and DCVMN Strengthen Health Resilience Through Global Partnership
BANDUNG, Indonesia, Oct. 25, 2025 /PRNewswire/ -- Through PT Bio Farma (Persero),Indonesia has played a strategic and sustained role in the Developing Countries Vaccine Manufacturers' Network (DCVMN), working to ensure equitable access to safe, high-quality, and affordable vaccines. Since DCVMN's...
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07BeLive Studios, NewUnivers and ChopChop Systems Sign Memorandum of Understanding at ATF 2025
[Picked up by 288 media titles]
2025-12-08 11:00Tiiny AI Reveals World's Smallest Personal AI Supercomputer, Verified by Guinness World Records
[Picked up by 286 media titles]
2025-12-10 16:00